News Sentiment

TNGX sentiment intelligence

Tango Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 28.56 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-8.0% over one week, +2.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -8.0% Price reacting lower
Trend fit Trend active 2.1% over four weeks
Fair value 206.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 32
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 8
www.marketscreener.com 5
simplywall.st 5
Simply Wall Street 4
Investing.com 3
TradingView 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 11
Analyst action 9
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Moomoo Direct company coverage

Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating

Mizuho has increased its price target for Tango Therapeutics (NASDAQ: TNGX) to $40, up from the previous $36, while maintaining an Outperform rating. This adjustment suggests a positive outlook on the company's future performance and stock valuation.

Tone
Positive 72/100
Event
Analyst action
Published
18 Jul 2026 05:09
Source
Moomoo
GuruFocus Direct company coverage

TNGX Maintained by Mizuho -- Price Target Raised to $40.00

Mizuho has maintained an "Outperform" rating for Tango Therapeutics (TNGX) and increased its price target to $40.00, reflecting optimism about the company's growth in cancer therapies. Despite the positive analyst sentiment, GuruFocus indicates that TNGX is significantly overvalu

Tone
Positive 58/100
Event
Analyst action
Published
17 Jul 2026 19:41
Source
GuruFocus
Investing.com Direct company coverage

Mizuho raises Tango Therapeutics stock price target on combo data

Mizuho has increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $40 from $36, maintaining an Outperform rating, based on promising new data for its drug combinations in pancreatic cancer. This comes amidst recent positive analyst revisions and a significant stock of

Tone
Positive 72/100
Event
Analyst action
Published
17 Jul 2026 11:40
Source
Investing.com
Investing.com Direct company coverage

JPMorgan initiates Tango Therapeutics stock at Overweight

JPMorgan initiated coverage on Tango Therapeutics Inc. (NASDAQ:TNGX) with an Overweight rating and a price target of $46.00, citing progress with its lead PRMT5 inhibitor vopimetostat and promising combination trial data. The company has seen significant stock growth, streamlined

Tone
Positive 75/100
Event
Analyst action
Published
15 Jul 2026 12:39
Source
Investing.com
Investing.com Nigeria Direct company coverage

JPMorgan initiates Tango Therapeutics stock at Overweight By Investing.com

JPMorgan initiated coverage on Tango Therapeutics Inc. (NASDAQ:TNGX) with an Overweight rating and a $46.00 price target, despite the stock's significant surge and being considered overvalued by InvestingPro analysis. The firm highlighted Tango's progress with its lead PRMT5 inhi

Tone
Positive 71/100
Event
Analyst action
Published
15 Jul 2026 12:11
Source
Investing.com Nigeria
GuruFocus Direct company coverage

TNGX Initiates Coverage On JP Morgan -- Rating Set to Overweight

JP Morgan has initiated coverage on Tango Therapeutics (TNGX) with an Overweight rating and a price target of $46.00. Despite this positive analyst recommendation, GuruFocus indicates that TNGX is significantly overvalued by 202.9%, with a GF Value of $9.79 against a current trad

Tone
Positive 65/100
Event
Analyst action
Published
15 Jul 2026 12:11
Source
GuruFocus
www.marketscreener.com Direct company coverage

JPMorgan Initiates Coverage on Tango Therapeutics With Overweight Rating, $46 Price Target

JPMorgan has initiated coverage on Tango Therapeutics (TNGX) with an Overweight rating and set a price target of $46. This positive outlook follows several recent developments for Tango Therapeutics, including its inclusion in various Russell indices. The company specializes in d

Tone
Positive 72/100
Event
Analyst action
Published
15 Jul 2026 07:25
Source
www.marketscreener.com
TradingKey Direct company coverage

Tango Therapeutics Inc (TNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Tango Therapeutics Inc (TNGX), detailing its current price momentum, support and resistance levels, and performance across various technical indicators and moving averages. As of July 15, 2026, TNGX has a price momentum score of 4.21,

Tone
Negative 33/100
Event
Market update
Published
14 Jul 2026 00:11
Source
TradingKey
Simply Wall Street Direct company coverage

Does Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions?

Tango Therapeutics (TNGX) was recently reclassified into several Russell growth indices, moving out of value and microcap segments. This shift frames TNGX as a high-growth, high-risk biotechnology narrative, potentially attracting growth-oriented institutional investors. The comp

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 09:10
Source
Simply Wall Street
Stocktwits Direct company coverage

TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside

Tango Therapeutics (TNGX) stock crashed 20% after reporting $0 revenue in Q1, missing Wall Street expectations. Despite this, several analysts like Leerink, Mizuho, and Wedbush raised their price targets and maintained "Outperform" ratings, citing factors like upcoming pancreatic

Tone
Positive 71/100
Event
Earnings
Published
07 Jul 2026 10:43
Source
Stocktwits
Simply Wall Street Direct company coverage

Is Tango Therapeutics (TNGX) Fully Valued On Russell Index Rebalancing?

Tango Therapeutics (TNGX) has experienced significant share price growth, up 48.07% over the past month and 235.27% year-to-date, due to its inclusion in Russell growth benchmarks. Despite a high Price-to-Book multiple of 11.1x, suggesting overvaluation compared to the industry a

Tone
Negative 38/100
Event
Market update
Published
07 Jul 2026 09:43
Source
Simply Wall Street
Investing.com Direct company coverage

Tango Therapeutics president Crystal Adam sells $798,908 in stock

Crystal Adam, President of Research & Development at Tango Therapeutics, sold 27,000 shares of company common stock for $798,908 after exercising stock options. The transactions were conducted under a pre-arranged trading plan, with shares sold in two blocks at weighted average p

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 08:39
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Tango Therapeutics Inc For: 2 July By Investing.com

This article reports on a Form 4 filing by Tango Therapeutics Inc., dated July 2. The filing indicates insider trading activity for the company, symbolized as TNGX, which saw a 1.63% increase. The brief announcement provides no further details about the nature of the transaction.

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 00:36
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Tango Therapeutics (TNGX) R&D president exercises options and sells 27,000 shares

Crystal Adam, President of R&D at Tango Therapeutics (TNGX), exercised stock options for 27,000 shares at $5.20 per share and subsequently sold all 27,000 shares in open-market transactions. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan, occurred at weighte

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 23:40
Source
Stock Titan
TradingView Direct company coverage

Price to book forward of Tango Therapeutics, Inc. – NASDAQ:TNGX

This article focuses on the "Price to book forward" metric for Tango Therapeutics, Inc. (NASDAQ:TNGX). It appears to be a financial data snippet from TradingView, providing an overview of the company's financial information within their platform. The content primarily shows the n

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:40
Source
TradingView
Market source Direct company coverage

Tango Therapeutics Rides a New Precision Oncology Trend in 2026

Tango Therapeutics is a key player in precision oncology, focusing on MTAP-deleted cancers with therapies like vopimetostat (TNG462) and TNG456. The company is using a synthetic-lethality approach and combination therapies, particularly for pancreatic, lung, and brain tumors, and

Tone
Positive 67/100
Event
Market update
Published
02 Jul 2026 14:50
Source
Market source
TradingView Direct company coverage

Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?

Tango Therapeutics (TNGX) has seen a dramatic rally in 2026 due to promising clinical progress with its drug vopimetostat, particularly for MTAP-deleted, RAS-mutant pancreatic cancer. Despite this, the company faces risks as it is still clinical-stage with no product revenues and

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 14:39
Source
TradingView
TradingView Direct company coverage

TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts

Tango Therapeutics (TNGX) is entering a crucial period, with its stock outlook primarily tied to the success of vopimetostat and key clinical updates expected in 2026. The company's strategy focuses on MTAP-deleted cancers with a narrowed pipeline, leading to higher concentration

Tone
Neutral 50/100
Event
Guidance
Published
02 Jul 2026 14:39
Source
TradingView
Simply Wall Street Direct company coverage

Tango Therapeutics (TNGX) Enters Russell Growth Indexes and Adds Biopharma Veteran Azelby to Board

Tango Therapeutics (TNGX) has been included in several Russell Growth benchmarks and simultaneously removed from Value and Microcap indexes in late June 2026, signaling a market perception shift towards it as a high-growth, high-risk biotech. Concurrently, the company appointed b

Tone
Positive 66/100
Event
Market update
Published
01 Jul 2026 05:40
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2500 Growth Benchmark

Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth Benchmark and Russell 3000E Growth Benchmark. This news comes alongside other index adjustments for the company, including being dropped from several

Tone
Positive 73/100
Event
Market update
Published
29 Jun 2026 19:39
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 2000 Growth Benchmark

Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 2000 Growth Benchmark. This news comes alongside several other announcements regarding the company's inclusion and exclusion from various Russell indices, including being dropped from the Russell Small Cap Co

Tone
Positive 66/100
Event
Market update
Published
29 Jun 2026 11:12
Source
www.marketscreener.com
marketscreener.com Direct company coverage

Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Benchmark

Tango Therapeutics, Inc. (NasdaqGM:TNGX) has been removed from the Russell Small Cap Comp Value Benchmark. This decision by S&P Capital IQ was announced on June 29, 2026, at 06:16 am EDT. Concurrently, the company was also added to the Russell 2000 Growth Benchmark and Russell 30

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 10:12
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Tango Therapeutics, Inc.(NasdaqGM: TNGX) added to Russell 3000 Growth Benchmark

Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been added to the Russell 3000 Growth Benchmark, as announced on June 28, 2026. This inclusion is part of several recent index adjustments, which also saw the company added to the Russell 2500 Growth Benchmark and dropped from other b

Tone
Positive 65/100
Event
Market update
Published
29 Jun 2026 07:10
Source
www.marketscreener.com
Simply Wall Street Direct company coverage

Tango Therapeutics (TNGX) Could Be 64% Below Fair Value As It Adds Robert Azelby

Tango Therapeutics (TNGX) recently appointed Robert Azelby to its Board of Directors, as it advances its investigational PRMT5 inhibitor vopimetostat. The company's share price has shown strong momentum, with significant returns over the last year. Simply Wall St's DCF model esti

Tone
Positive 66/100
Event
Regulatory and legal
Published
29 Jun 2026 06:39
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Tango Therapeutics, Inc.(NasdaqGM: TNGX) dropped from Russell 2500 Value Benchmark

Tango Therapeutics, Inc. (NasdaqGM: TNGX) has been removed from the Russell 2500 Value Benchmark, as reported by S&P Capital IQ on June 28, 2026. This exclusion is part of several benchmark adjustments for the company around the same date, including additions to growth benchmarks

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 21:10
Source
www.marketscreener.com